ADMA Biologics (ADMA) Misses Q3 EPS by 9c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of ($0.48), $0.09 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.85 million versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c